Acute Leukemias

Acute Leukemias

A collection of features and news articles published in ASH Clinical News related to acute leukemias.

Study Finds Higher Rates of Leukemia in 9/11 Responders and Recovery Workers

Investigators  discovered an increase in the incidence of leukemia in first responders and other recovery workers who were at the World Trade Center (WTC)...

Early Intensification of Intrathecal Chemotherapy Reduces Risk of Relapse in Pediatric ALL

Two additional doses of intrathecal therapy early during induction treatment for children with newly diagnosed acute lymphocytic leukemia (ALL) who were at increased risk...
WIB_icon

Achievement of MRD Negativity Predicts Favorable Prognosis in RUNX1-RUNX1T1+ AML

In patients with acute myeloid leukemia (AML) with t(8;21)(q22;q22.1)/RUNX1-RUNX1T1+ fusion, serial assessment of measurable residual disease (MRD) can identify people at a high risk...

Updates on ASH Clinical Practice Guidelines in Development

In 2019, the American Society of Hematology (ASH) continued its efforts to develop and publish evidence-based clinical practice guidelines to help practicing hematologists and...

Are Clinical Trial Exclusion Criteria for Patients With AML Too Strict?

Watch our interview with Abby Statler, MD, MPH. In a study presented at the 2019 ASH Annual Meeting, researchers found that certain comorbidities in patients...

QUAZAR: Oral Azacitidine Maintenance Improves Survival in Transplant-Ineligible AML

According to research presented as a late-breaking abstract at the 2019 ASH Annual Meeting, treatment with CC-486, an oral formulation of the hypomethylating agent...

Is Blinatumomab a New Standard of Care for Young Patients With B-Cell ALL?

Compared with standard chemotherapy, blinatumomab as consolidation prior to hematopoietic cell transplantation (HCT) is associated with fewer severe toxicities, higher response rates, and longer...

MRD Response Predicts Survival in Blinatumomab-Treated Patients With Relapsed/Refractory ALL

In patients with relapsed/refractory B-cell precursor acute lymphocytic leukemia (ALL) who are treated with blinatumomab, achieving minimal residual disease (MRD) was associated with improved...

David Sallman: Magrolimab Plus Azacitidine Effective in MDS and AML

Treatment with the combination of the CD47-targeting antibody magrolimab and azacitidine induced high response rates, particularly in patients with myelodysplastic syndromes. David A. Sallman,...

Abby Statler: Are Clinical Trials Exclusion Criteria for AML Too Strict?

Abby Statler, PhD, MPH, discusses findings from an analysis of common clinical trial exclusion criteria and outcomes in clinical trials, which suggest that eligibility...
Advertisement

Current Issue

January 2020 Annual Meeting Edition

This issue features highlights from the 2019 ASH Annual Meeting, reflections on physician wellness, and more.